Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Braf kinase-inactive mutant induces lung adenocarcinoma.

Nature - 10 Aug 2017

Nieto Patricia, Ambrogio Chiara, Esteban-Burgos Laura, Gómez-López Gonzalo, Blasco María Teresa, Yao Zhan, Marais Richard, Rosen Neal, Chiarle Roberto, Pisano David G, Barbacid Mariano, Santamaría David

Abstract excerpt

The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies. Yet these tumours harbour a number of alterations without obvious oncogenic function including BRAF-inactivating mutations. Inactivating BRAF mutants in lung predominate over the activating V600E mutant that is frequently observed in other tumour...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Genes, Neurofibromatosis 1

Share to Loss of Function Mutation

Share to MAP Kinase Signaling System

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 28783725
DOI: 10.1038/nature23297
PMCID: PMC5648056

Genes

BRAF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Braf kinase-inactive mutant induces lung adenocarcinoma.PMID 28783725Read ↗

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Semantic proximity Read ↗

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.Semantic proximity Read ↗

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilitiesSemantic proximity Read ↗

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.Semantic proximity Read ↗

Early differential responses elicited by BRAFV600E in adult mouse models.Semantic proximity Read ↗

Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.Semantic proximity Read ↗

FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice.Semantic proximity Read ↗

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.Semantic proximity Read ↗

Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo.Semantic proximity Read ↗

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinomaSemantic proximity Read ↗

<i>KRAS</i> signalling in malignant pleural mesotheliomaSemantic proximity Read ↗

The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.